TrialCannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Trial details
- Registry ID
- NCT04615949
- Phase
- Phase 2, Phase 3
Drug research
Cannabidiol, pharmaceutically produced with < 5 ppm THC
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as CardiolRx
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949 | CRDL | Phase 2, Phase 3 | Terminated | 2022-11-30Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |